Nippon rinsho. Japanese journal of clinical medicine 2013-04-01

[Paliperidone, risperidone].

Katsuya Takeuchi, Katsumi Sanjo, Akio Sakai

文献索引：Nihon Rinsho. 71(4) , 654-9, (2013)

全文：HTML全文

摘要

Risperidone, a serotonin-dopamine antagonist, is effective in preventing delusions and hallucinations by D2 receptor antagonism and treating negative symptoms by 5-HT2A receptor antagonism. It is less likely to produce extrapyramidal symptoms than conventional antipsychotics, enabling safe drug therapy for schizophrenia. Paliperidone, based on 9OH-risperidone(major metabolite of risperidone), was developed to make the best use of the high therapeutic efficacy of Risperdal and enable continued treatment with lower prevalence of adverse events. Its mechanism of action as an extended-release tablet ensures slow release of the active ingredient, contributing to the lower prevalence of adverse events. With these pharmacological characteristics in mind, the two drugs can serve as safe and effective drug therapy.